Analysis

Organon & Co. (OGN) Stock Analysis

Organon & Co. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to OGN.

websiteOGN/analysis/OGN

Organon & Co.

Organon & Co. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to OGN.

Stock profile

Ticker

OGN

Asset type

Stock

Market cap

$3.53B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Organon & Co. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • OGN primary listing
  • 7XP
  • A3CPKP
  • 0A9W
  • 1OGN
  • 4OGN

Latest Organon & Co. news

Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab in...

KIRKLAND, Quebec & SHANGHAI, June 23, 2026--Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA

Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

JERSEY CITY, N.J., June 22, 2026--Organon completes agreement to license MIUDELLA®, Sebela’s hormone-free IUD, expanding its long-acting reversible contraception portfolio

Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in...

INCHEON, South Korea & KIRKLAND, Quebec, June 18, 2026--Organon and Samsung Bioepis expand agreement to commercialize PYZCHIVA® (ustekinumab), a biosimilar referencing STELARA® ...

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Synd...

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and

Organon to Present New Research on Access and Value at ISPOR 2026

JERSEY CITY, N.J., May 15, 2026--Organon to present 8 abstracts on affordability, access and adoption across women’s health, biosimilar and general medicines portfolio at ISPOR ...

Research sections

Valuation

Review valuation context for Organon & Co..

Future growth

Review future growth context for Organon & Co..

Past performance

Review past performance context for Organon & Co..

Financial health

Review financial health context for Organon & Co..

Dividend

Review dividend context for Organon & Co..

Management

Review management context for Organon & Co..

Ownership

Review ownership context for Organon & Co..

Other information

Review other information context for Organon & Co..

Community

Review community context for Organon & Co..